Better detection and cancer-risk prediction for Barrett's esophagus
Academic-Industrial Partnership for Barrett's Esophagus Detection and Risk Assessment
['FUNDING_R01'] · JOHNS HOPKINS UNIVERSITY · NIH-11294320
This project tests a lab-based prognostic test to help people with Barrett's esophagus learn their future chance of developing esophageal cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11294320 on ClinicalTrials.gov |
What this research studies
If you have Barrett's esophagus, this project continues a Johns Hopkins partnership with industry to improve a lab test that predicts who is most likely to progress toward esophageal cancer. You may be asked to provide tissue or other biospecimens and clinical information so researchers can compare the test's results with standard pathology. The team will refine biomarkers and algorithms—especially for people with low-grade dysplasia where current pathology is unclear—and validate the approach in clinical samples. The goal is clearer, more personalized risk information to guide follow-up and treatment decisions.
Who could benefit from this research
Good fit: People diagnosed with Barrett's esophagus—particularly those with low-grade dysplasia, uncertain biopsy results, or who want clearer long-term risk information—are the ideal candidates.
Not a fit: People without Barrett's esophagus, those with fully treated advanced cancer, or individuals unwilling to provide samples or clinical follow-up are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, the work could give patients clearer, personalized cancer-risk results so high-risk people get timely treatment and low-risk people avoid unnecessary procedures.
How similar studies have performed: Prior work from this team led to a commercial prognostic product (Capsulomics/Previse) showing promise, but prediction for low-grade dysplasia remains imperfect and needs further clinical validation.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MELTZER, STEPHEN J — JOHNS HOPKINS UNIVERSITY
- Study coordinator: MELTZER, STEPHEN J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Barrett Syndrome